BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double‐Blind Randomised Interventional Phase 2b Trial

BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double‐Blind Randomised Interventional Phase 2b Trial

ABSTRACT Background Sarcopenia is a progressive muscle disorder that may lead to mobility disability. No pharmaceutical interventions are currently available, and treatment relies on physical exercise and nutrition. The aim of SARA‐INT was to investigate whether BIO101 (20‐hydroxyecdysone), an activ...

Full description

Saved in:
Bibliographic Details
Main Authors: Roger A. Fielding, Michael M. Dao, Kevin Cannon, Moise Desvarieux, Sam S. Miller, Michael Paul Gimness, Donald M. Brandon, Dennis T. Villareal, Olivier Bruyere, Ivan Bautmans, Kyle Rickner, Robert Perry, Stephen B. Kritchevsky, Nicolas Musi, Joe M. Chehade, Judith L. Kirstein, Evelien Gielen, Paul Pickrell, Pierre Dilda, Rene Lafont, Carole Margalef, Yves Rolland, Susanna Del Signore, Jean Mariani, Samuel Agus, Cendrine Tourette, Waly Dioh, Rob vanMaanen, Stanislas Veillet
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Journal of Cachexia, Sarcopenia and Muscle
Subjects:
20‐hydroxyecdysone
BIO101
clinical trial
gait speed
mobility disability
sarcopenia
Online Access:https://doi.org/10.1002/jcsm.13750
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/jcsm.13750

Similar Items